Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Acute Lymphoblastic Leukemia, Adult

Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Acute Lymphoblastic Leukemia, Adult cohort.

Asset / SponsorPhaseRating
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BB
Ponatinib
PETHEMA Foundation
Phase 3B
cc-5013
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Equine Atg
Shanxi Bethune Hospital
Phase 2/3CCC
Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3CCC

View all 15 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →